Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059388
Filing Date
2025-04-28
Accepted
2025-04-28 16:59:45
Documents
21
Period of Report
2025-05-27

Document Format Files

Seq Description Document Type Size
1 DEF 14A apto-20250428.htm   iXBRL DEF 14A 1715305
2 GRAPHIC img240650062_0.jpg GRAPHIC 6070
3 GRAPHIC img240650062_1.jpg GRAPHIC 1534
4 GRAPHIC img240650062_2.jpg GRAPHIC 354855
5 GRAPHIC img240650062_3.jpg GRAPHIC 360335
6 GRAPHIC img240650062_4.jpg GRAPHIC 2786
7 GRAPHIC img240650062_5.jpg GRAPHIC 3130
8 GRAPHIC img240650062_6.jpg GRAPHIC 752998
9 GRAPHIC img240650062_7.jpg GRAPHIC 671868
  Complete submission text file 0000950170-25-059388.txt   7542192

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apto-20250428.xsd EX-101.SCH 7920
24 EXTRACTED XBRL INSTANCE DOCUMENT apto-20250428_htm.xml XML 145634
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-32001 | Film No.: 25881347
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)